 | Up a level |
Fiaschetti, G; Castelletti, D; Zoller, S; Schramm, A; Schroeder, C; Nagaishi, M; Stearns, D; Mittelbronn, M; Eggert, A; Westermann, F; Ohgaki, H; Shalaby, T; Pruschy, M; Arcaro, A; Grotzer, M A (2023). Correction: Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. Oncogene, 42(2), p. 168. Nature Publishing Group 10.1038/s41388-022-02555-9
Salm, F; Cwiek, P; Ghosal, A; Lucia Buccarello, A; Largey, F; Wotzkow, C; Höland, K; Styp-Rekowska, B; Djonov, V; Zlobec, I; Bodmer, N; Gross, N; Westermann, F; Schäfer, S C; Arcaro, A (2012). RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance. Oncogene, 32(34), pp. 3944-3953. Basingstoke, UK: Nature Publishing Group 10.1038/onc.2012.416
Höland, K; Salm, F; Arcaro, A (2011). The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors. Current cancer drug targets, 11(8), pp. 894-918. Hilversum: Bentham Science Publishers
Fiaschetti, G; Castelletti, D; Zoller, S; Schramm, A; Schroeder, C; Nagaishi, M; Stearns, D; Mittelbronn, M; Eggert, A; Westermann, F; Ohgaki, H; Shalaby, T; Pruschy, M; Arcaro, A; Grotzer, M A (2011). Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. Oncogene, 30(25), pp. 2823-35. Basingstoke, UK: Nature Publishing Group 10.1038/onc.2011.10
Fiaschetti, G; Grotzer, M A; Shalaby, T; Castelletti, D; Arcaro, A (2011). Quassinoids: From traditional drugs to new cancer therapeutics. Current medicinal chemistry, 18(3), pp. 316-28. Schiphol: Bentham 10.2174/092986711794839205
